US biopharmaceutical company Sterotherapeutics announced on Monday that it has launched a Phase 2 clinical trial of ST-002, a novel drug candidate for patients with Cushing's Syndrome, a rare endocrine disorder with very limited available therapeutic options.
An Investigators Meeting to start the study has taken place in Athens, Greece, when clinical investigators, research coordinators and stakeholders discussed trial objectives, protocol details and best practices.
The Phase 2 trial is intended to assess the safety, efficacy and tolerability of ST-002 in patients with Cushing's syndrome.
Caused by prolonged exposure to excessive cortisol levels, Cushing's syndrome can lead to severe complications such as diabetes, hypertension, osteoporosis and increased mortality if left untreated.
Sterotherapeutics has received orphan drug designation for ST-002 from the US Food and Drug Administration (FDA).
Australia declines approval for BioArctic and Eisai's Alzheimer's drug lecanemab
AstraZeneca's Imfinzi recommended for EU approval in resectable NSCLC treatment
Fapon Biopharma's FP008 IND application receives US FDA approval
AbbVie receives positive CHMP opinion for upadacitinib in giant cell arteritis
Avobis Bio LLC receives Fast Track designation from FDA for AVB-114
US FDA grants Priority Review to Sobi's sBLA for Gamifant in Still's disease-related MAS
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
LSPedia secures MMCAP Infuse DSCSA Compliance contract
FDA accepts Telix Pharmaceuticals' BLA for Zircaix and grants Priority Review
Sterotherapeutics launches Phase 2 clinical trial of ST-002 for Cushing's Syndrome